Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

Briefs: Emcure Pharmaceuticals and Gland Pharma

Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility

Emcure to acquire remaining stake in Zuventus Healthcare

The transaction is expected to close in Q2 FY 2026

Emcure partners with Vidya Balan for Arth supplements,

Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues

Briefs: Emcure and Relonchem

USFDA inspection at Emcure Pharmaceuticals API facility

M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness

Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages

Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad

The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations

Emcure and MS Dhoni drive India’s fight against Anemia

Emcure has launched an awareness campaign to help spread the word about male anemia

Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records